SequelSEC

Cogent Biosciences, Inc. COGT

Pharmaceutical Preparations · CIK 0001622229 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$7.87M
Fiscal year ended 2020-12-31
Operating income
-$82.20M
Fiscal year ended 2020-12-31
Free cash flow
Unavailable
Fiscal year ended 2020-12-31

Cogent Biosciences, Inc. (COGT) reported revenue of $7.87M and net income of -$74.81M for the fiscal year ended 2020-12-31. This page shows 4 annual periods of income statement, balance sheet and cash flow figures normalized from Cogent Biosciences, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Cogent Biosciences, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2020-12-312019-12-312018-12-312017-12-31
Revenue$7.87M$22.50M$9.73M$8.36M
Cost of revenueUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailable
Operating income-$82.20M-$32.18M-$36.00M-$26.15M
Net income-$74.81M-$31.83M-$34.53M-$25.49M
Research & development$25.74M$43.71M$38.28M$29.83M
Weighted-average diluted sharesUnavailableUnavailableUnavailableUnavailable
Pretax incomeUnavailableUnavailableUnavailableUnavailable
Income tax expenseUnavailableUnavailableUnavailableUnavailable
Diluted EPSUnavailableUnavailableUnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailable
General & administrative$17.42M$10.97M$7.45M$4.68M
Selling & marketingUnavailableUnavailableUnavailableUnavailable

Balance

Cogent Biosciences, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2020-12-312019-12-312018-12-312017-12-31
Cash & equivalents$242.19M$37.42M$55.67M$28.27M
Total assets$250.92M$49.42M$85.93M$49.12M
Current assets$244.91M$40.59M$81.00M$42.38M
Total liabilities$16.25M$17.66M$25.69M$20.81M
Current liabilities$13.09M$13.25M$24.94M$11.19M
Total equity incl. NCI$234.67M$31.76M$60.23M-$48.85M
Temporary (mezzanine) equityUnavailableUnavailableUnavailable$77.15M
InventoryUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailable$2.00M$1.67M$830.00K
GoodwillUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailable
Accounts payable$732.00K$3.18M$1.52M$1.35M

Cash flow

Cogent Biosciences, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2020-12-312019-12-312018-12-312017-12-31
Operating cash flow-$35.85M-$41.51M-$32.49M-$25.84M
Capital expendituresUnavailable$33.00K$549.00K$912.00K
Investing cash flow$8.42M$23.16M-$10.53M$13.59M
Financing cash flow$232.20M$108.00K$70.35M-$729.00K
Net change in cash$204.77M-$18.25M$27.33M-$12.98M
Stock-based compensation$6.02M$3.24M$3.09M$1.34M
Common dividends paidUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$720.00K$1.29M$1.32M$1.17M

Derived

Cogent Biosciences, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2020-12-312019-12-312018-12-312017-12-31
Free cash flowUnavailable-$41.55M-$33.04M-$26.75M
Gross marginUnavailableUnavailableUnavailableUnavailable
Operating margin-1044.3%-143.0%-369.9%-312.8%
FCF marginUnavailable-184.7%-339.4%-319.9%
SBC / revenue76.4%14.4%31.7%16.0%
Current ratio18.70x3.06x3.25x3.79x
Revenue YoY growth-65.0%131.1%16.4%Unavailable
Net margin-950.4%-141.5%-354.8%-304.9%
R&D / revenue327.0%194.3%393.3%356.8%
CapEx / revenueUnavailable0.1%5.6%10.9%
Long-term debt / equityUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open COGT in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-10View SEC filing
10-Q · Filed 2026-05-05View SEC filing
10-K · Filed 2026-02-17View SEC filing
10-Q · Filed 2025-11-07View SEC filing
10-Q · Filed 2025-08-05View SEC filing
10-Q · Filed 2025-05-06View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.